The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer

Timur Mitin, Ananya Choudhury

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Patients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians’ and patients’ preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies. Methods: We provide a narrative review of clinical data pertaining to the biomarkers in bladder preservation management of MIBC. Results: There are currently no validated and clinically used biological markers used for stratification of radical bladder treatment and selection of bladder-preserving therapies. This article summarizes biomarkers that could have a potential clinical utility—PD-L1, molecular subtypes, Ki-67, MRE-11 and markers of hypoxia—and offers a hypothetical pathway model for a marker-driven precision management of medically operable patients with a newly diagnosed MIBC. Conclusion: When selecting the optimal cancer treatment, both patient and tumor factors need to be considered. Once validated, biological markers will help clinicians tailor the management of MIBC to individual patients.

Original languageEnglish (US)
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Biomarkers
Muscles
Cystectomy
Therapeutics
Neoplasms
Patient Preference
Radiotherapy
Physicians
Recurrence
Drug Therapy

Keywords

  • Biomarkers
  • Bladder cancer
  • Bladder preservation
  • Muscle-invasive bladder cancer
  • Precision oncology
  • Radiation oncology

ASJC Scopus subject areas

  • Urology

Cite this

The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. / Mitin, Timur; Choudhury, Ananya.

In: World Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

@article{ffdc8b5021e04048a80482e08a4dfa81,
title = "The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer",
abstract = "Purpose: Patients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians’ and patients’ preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies. Methods: We provide a narrative review of clinical data pertaining to the biomarkers in bladder preservation management of MIBC. Results: There are currently no validated and clinically used biological markers used for stratification of radical bladder treatment and selection of bladder-preserving therapies. This article summarizes biomarkers that could have a potential clinical utility—PD-L1, molecular subtypes, Ki-67, MRE-11 and markers of hypoxia—and offers a hypothetical pathway model for a marker-driven precision management of medically operable patients with a newly diagnosed MIBC. Conclusion: When selecting the optimal cancer treatment, both patient and tumor factors need to be considered. Once validated, biological markers will help clinicians tailor the management of MIBC to individual patients.",
keywords = "Biomarkers, Bladder cancer, Bladder preservation, Muscle-invasive bladder cancer, Precision oncology, Radiation oncology",
author = "Timur Mitin and Ananya Choudhury",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00345-018-2480-7",
language = "English (US)",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer

AU - Mitin, Timur

AU - Choudhury, Ananya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Patients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians’ and patients’ preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies. Methods: We provide a narrative review of clinical data pertaining to the biomarkers in bladder preservation management of MIBC. Results: There are currently no validated and clinically used biological markers used for stratification of radical bladder treatment and selection of bladder-preserving therapies. This article summarizes biomarkers that could have a potential clinical utility—PD-L1, molecular subtypes, Ki-67, MRE-11 and markers of hypoxia—and offers a hypothetical pathway model for a marker-driven precision management of medically operable patients with a newly diagnosed MIBC. Conclusion: When selecting the optimal cancer treatment, both patient and tumor factors need to be considered. Once validated, biological markers will help clinicians tailor the management of MIBC to individual patients.

AB - Purpose: Patients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians’ and patients’ preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies. Methods: We provide a narrative review of clinical data pertaining to the biomarkers in bladder preservation management of MIBC. Results: There are currently no validated and clinically used biological markers used for stratification of radical bladder treatment and selection of bladder-preserving therapies. This article summarizes biomarkers that could have a potential clinical utility—PD-L1, molecular subtypes, Ki-67, MRE-11 and markers of hypoxia—and offers a hypothetical pathway model for a marker-driven precision management of medically operable patients with a newly diagnosed MIBC. Conclusion: When selecting the optimal cancer treatment, both patient and tumor factors need to be considered. Once validated, biological markers will help clinicians tailor the management of MIBC to individual patients.

KW - Biomarkers

KW - Bladder cancer

KW - Bladder preservation

KW - Muscle-invasive bladder cancer

KW - Precision oncology

KW - Radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=85053597530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053597530&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2480-7

DO - 10.1007/s00345-018-2480-7

M3 - Article

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -